6,133 Shares in Humana Inc. (NYSE:HUM) Acquired by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. acquired a new position in Humana Inc. (NYSE:HUM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,133 shares of the insurance provider’s stock, valued at approximately $2,808,000. Humana makes up about 1.0% of Lecap Asset Management Ltd.’s investment portfolio, making the stock its 3rd biggest holding.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp boosted its position in Humana by 0.5% during the 1st quarter. State Street Corp now owns 5,708,167 shares of the insurance provider’s stock valued at $2,776,072,000 after acquiring an additional 25,832 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Humana by 0.8% in the 1st quarter. Geode Capital Management LLC now owns 2,234,477 shares of the insurance provider’s stock worth $1,082,060,000 after purchasing an additional 16,692 shares in the last quarter. Morgan Stanley boosted its position in shares of Humana by 6.2% in the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock worth $992,938,000 after purchasing an additional 119,760 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after purchasing an additional 402,559 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Humana in the 4th quarter worth $690,516,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of Humana stock traded down $3.70 on Friday, hitting $312.59. The company’s stock had a trading volume of 1,467,617 shares, compared to its average volume of 1,740,352. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a market capitalization of $37.71 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45. The firm has a fifty day moving average price of $347.21 and a 200-day moving average price of $429.79.

Humana (NYSE:HUM) last issued its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). The company had revenue of $26.46 billion for the quarter, compared to analyst estimates of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.62 earnings per share. As a group, sell-side analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Wednesday, March 27th. Humana’s payout ratio is 17.86%.

Insider Buying and Selling at Humana

In related news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.32% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of recent analyst reports. Bank of America reissued a “neutral” rating and issued a $342.00 price objective (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Argus cut Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. StockNews.com cut Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. TheStreet lowered Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Finally, Stephens reduced their target price on Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research note on Friday, January 26th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $465.42.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.